A landmark ICMR study provides critical economic evidence for a major shift in India's fight against drug-resistant tuberculosis (DR-TB). It finds that newer, 6-month all-oral drug regimens (BPaL/BPaLM) are not only more effective but also cost-saving for the health system compared to older, longer treatments. This is a game-changer for India's National TB Elimination Programme (NTEP), promising better patient outcomes and faster progress towards the 2025 elimination goal.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Study Conducted By: ICMR-National Institute for Research in Tuberculosis (ICMR-NIRT)
- ›Regimen Duration: 6 months (vs. 9-20 months)
- ›Target this Data: 6-month duration of new regimens; BPaL saves ₹379 per QALY.
- ›Target this Nodal Body: ICMR-National Institute for Research in Tuberculosis (ICMR-NIRT).
- ›Target this Legal Point: National TB Elimination Programme (NTEP) - India's goal is elimination by 2025.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.